Earnings Call Summary | Cytosorbents(CTSO.US) Q1 2024 Earnings Conference
Earnings Call Summary | Cytosorbents(CTSO.US) Q1 2024 Earnings Conference
The following is a summary of the Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript:
以下是細胞吸附劑公司（CTSO）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Cytosorbents Corporation experienced a 14% increase in product sales in Q1 2024, rising from $7.9 million to $9 million. Additionally, a 22% sequential increase was reported from Q4 2023.
The company saw an increase in product gross margins to 76%, an improvement from the previous year's 68% in Q1.
By the end of Q1, the company had $10.1 million in cash, including $1.5 million in restricted cash, which is expected to cover operations into Q4 2024.
Total product sales for this quarter were mainly driven by developments in direct sales in Europe and multiple distributor countries.
2024年第一季度，Cytosorbents Corporation的產品銷售額增長了14％，從790萬美元增至900萬美元。此外，據報道，自2023年第四季度以來，連續增長了22％。
該公司的產品毛利率增長至76％，較去年第一季度的68％有所改善。
截至第一季度末，該公司擁有1,010萬澳元的現金，其中包括150萬澳元的限制性現金，預計將涵蓋2024年第四季度的運營。
本季度的產品總銷售主要是由歐洲和多個分銷國直銷的發展推動的。
Business Progress:
業務進展：
Cytosorbents presented its STAR-T data at the American Association for Thoracic Surgery. It is preparing to submit marketing applications for the DrugSorb-ATR system to FDA and Health Canada in Q3.
The company had delivered over 237,000 devices by Q1 and plans to reach a quarter of a million devices by year's end.
Introduction of the PuriFi hemoperfusion pump is planned in selected international countries. Positive customer response has been reported on new data on CytoSorb in acute liver disease, heart transplant, and septic shock.
Regulatory submission preparation is at an advanced stage, aided by productive interactions with the FDA. Initiatives continue to reach new customer groups and expand indications.
Company anticipates PuriFi system will drive sales of CytoSorb devices, especially in regions with fewer dialysis infrastructures. Submissions for DrugSorb to FDA and Health Canada are planned regardless of the distinct approval timelines of both entities.
Cytosorbents在美國胸外科學會上公佈了其STAR-T數據。它正準備在第三季度向美國食品藥品管理局和加拿大衛生部提交DrugSorb-ATR系統的上市申請。
截至第一季度，該公司已交付超過23.7萬臺設備，並計劃到年底達到25萬臺設備。
計劃在部分國際國家推出PuriFi血液灌注泵。根據CytoSorb在急性肝病、心臟移植和感染性休克中的新數據，客戶反應良好。
在與美國食品和藥物管理局富有成效的互動的幫助下，監管申報準備工作已進入後期階段。各項舉措繼續覆蓋新的客戶群體，並擴大了覆蓋範圍。
該公司預計，PuriFi系統將推動CytoSorb設備的銷售，尤其是在透析基礎設施較少的地區。無論兩個實體的批准時間表有何不同，都計劃向美國食品藥品管理局和加拿大衛生部提交DrugSorb的申請。
More details: Cytosorbents IR
更多詳情： 細胞吸附劑 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。